Clinical trial of bleomycin (NSC-125066) in the treatment of metastatic renal carcinoma.

This study had the limited aim of ascertaining the efficacy of bleomycin in controlling m etastatic renal carcinoma. Fifteen patients received bleomycin intramuscularly and five patients received the drug via continuous infusion. Only two patients had responses, both mixed. We concluded that the therapeutic value of bleomycin in the treatment of advanced renal carcinoma is negligible.